Stories

Prohibition often promises fewer problems, but the aftermath tells a different story. Once safer nicotine products are pushed out of legal reach, people do not simply stop wanting them — they find other routes, often with less oversight and more risk. For smokers, that can mean returning to cigarettes or relying on unregulated supply. The real test is not whether prohibition sounds protective, but whether it leaves people safer than before.

One letter can expose a much larger failure. When thousands of people who smoke are reduced to policy abstractions, the most important question is often left unanswered: what options are they actually being given? Tobacco harm reduction is not only about products or regulation; it is about whether public health listens to the people most affected by its decisions. A system that speaks for smokers without hearing them is unlikely to help them move away from harm.

Sweden’s challenge to Poland’s tough vape and nicotine restrictions is more than a procedural dispute. It raises a fundamental question for Europe: should countries with some of the best smoking outcomes be ignored when they point to the role of safer nicotine products? With tens of thousands of smoking-related deaths still recorded each year, policy should be guided by evidence of what reduces harm, not by reflexive restrictions on every new product. Europe should learn from success before legislating against it.

Every cigarette avoided is a risk reduction, even when the alternative is not risk-free. That is the point often lost in vaping debates. For adults who smoke, the comparison should begin with continued exposure to combustion, not an impossible standard of harmlessness. Public health should ask which choices reduce harm in real life, not which ones fit a perfect abstinence model.

Flavoured nicotine pouches receiving FDA authorisation complicates the idea that flavour alone should make a product unacceptable. The decision suggests that regulators can assess smoke-free products on evidence, exposure and population-level impact rather than category assumptions. Adult smokers need options that are both lower risk and acceptable enough to support switching. If authorisation is based on science, policy should allow that science to be communicated clearly.

Recognising that nicotine products differ in risk is only the first step. The harder task is ensuring that legislation reflects that distinction in practice. When smoke-free products are regulated as though they are equivalent to combustible cigarettes, policy loses the opportunity to encourage lower-risk choices while maintaining strong safeguards for young people. Evidence-based regulation should distinguish products according to their risk profile, not simply group them under the same label.

Ireland’s de facto vape flavour ban has hit a pause because other EU countries are asking the proportionality question. Italy and Greece’s objections highlight a wider concern: whether national restrictions on safer nicotine products can be justified when they may reduce adult switching and fragment the single market. Youth protection remains important, but it should be pursued through targeted enforcement rather than broad measures that remove useful alternatives. A delay is not a defeat for public health; it is a chance to get the policy right.

India’s tobacco burden remains enormous, yet people who vape continue to face punishment instead of proportionate policy. Criminalising or heavily restricting lower-risk alternatives does not make nicotine demand disappear; it narrows the legal routes away from combustible tobacco. A country with high tobacco use needs more harm reduction, not fewer options for adults trying to reduce risk. Public health should focus on moving people away from the deadliest products, not penalising those who choose a safer path.

Quitting nicotine and quitting smoking are not the same public health outcome. A person may continue using nicotine while dramatically reducing exposure to the toxicants created by burning tobacco. That distinction matters because insisting on nicotine abstinence as the only acceptable goal can overlook meaningful reductions in disease risk. For many smokers, the first priority should be leaving combustion behind — even if nicotine use does not end immediately.

Australia’s smoking and vaping policy has created a system where cigarettes remain easy to buy, while safer alternatives are treated as a problem to be contained. That contradiction has weakened trust, fuelled illicit supply and made switching harder for adults who smoke. Reform should start with a simple principle: regulate nicotine products according to risk, not political discomfort. A policy that keeps the most harmful product as the easiest option is not protecting public health.